Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part 1: Oral solutions

Journal of Pharmaceutical Sciences

Volumn 100, Issue 12, 2011, Pages 5324-5345

  Thelen, Kirstin ^a,b   Coboeken, Katrin ^b   Willmann, Stefan ^b   Burghaus, Rolf ^c   Dressman, Jennifer B ^a   Lippert, Jörg ^b  

^a GOETHE UNIVERSITY   (Germany)

^b BAYER AG   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Absorption; Computational ADME; Gastrointestinal tract; Mathematical models; Modeling; Oral absorption; PBPK; Pharmacokinetics; Prediction; Simulation

Indexed keywords

ACICLOVIR; AMOXICILLIN; AMPICILLIN; CAFFEINE; CEFADROXIL; CEFALEXIN; CIMETIDINE; DICLOFENAC; DOXORUBICIN; FUROSEMIDE; PARACETAMOL; PHENOBARBITAL; RANITIDINE; SALAZOSULFAPYRIDINE; THEOPHYLLINE;

ABSORPTION; ARTICLE; COMPUTER PROGRAM; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRACT FUNCTION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INTESTINE MUCOSA; NORMAL HUMAN; ORAL SOLUTION; PH; PHYSICAL CHEMISTRY; SECRETION; SOLUTION AND SOLUBILITY;

EID: 80054738759     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22726     Document Type: Article

References (190)

1. Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50 (Suppl 1):S41-S67.
2. Yu LX, Lipka E, Crison JR, Amidon GL. 1996. Transport approaches to the biopharmaceutical design of oral drug delivery systems: Prediction of intestinal absorption. Adv Drug Deliv Rev 19:359-376.
3. Grass GM. 1997. Simulation models to predict oral drug absorption from in vitro data. Adv Drug Deliv Rev 23:199-219.
4. Timony G, Norris D, Leesman G, Retajczyk R, Tran S, Chen Y, Lee Y, Johnson N, Castelo J, Lee K, Christopher R, Sinko PJ, Grass GM. 2000. Development and validation of the physiologically based iDEA predictive model. AAPS PharmSci 2.
5. Jamei M, Yang J, Turner D, Yeo KR, Tucker GT, Rostami-Hodjegan A. 2007. A novel physiologically-based model for predicting oral drug absorption: The advanced dissolution, absorption, and metabolism (ADAM) model. 4th World conference on drug absorption, transport and delivery. Kanazawa, Japan.
6. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. 2009. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211-223.
7. Johnson KC. 2003. Dissolution and absorption modeling: Model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption. Drug Dev Ind Pharm 29:833-842.
8. Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W. 2003. PK-Sim: A physiologically based pharmacokinetic ́whole-body' model. Biosilico 1:121-124.
9. Willmann S, Schmitt W, Keldenich J, Dressman JB. 2003. A physiological model for simulating gastrointestinal flow and drug absorption in rats. Pharm Res 20:1766-1771.
10. Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB. 2004. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 47:4022-4031.
11. Parrott N, Lave T. 2008. Applications of physiologically based absorption models in drug discovery and development. Mol Pharm 5:760-775.
12. Edginton AN, Theil FP, Schmitt W, Willmann S. 2008. Whole body physiologically-based pharmacokinetic models: Their use in clinical drug development. Expert Opin Drug Metab Toxicol 4:1143-1152.
13. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, Tucker G. 2009. Population-based mechanistic prediction of oral drug absorption. AAPS J 11:225-237.
14. Wang J, Flanagan DR. 1999. General solution for diffusion-controlled dissolution of spherical particles. 1. Theory. J Pharm Sci 88:731-738.
15. Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, Gaub T, Goerlitz L, Jaeger J, Loosen R, Ludewig B, Meyer M, Niederalt C, Sevestre M, Siegmund H, Solodenko J, Thelen K, Telle U, Weiss W, Wendl T, Willmann S, Lippert J. 2011. A computational systems biology software platform for multiscale modeling and simulation: Integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol 2:4.
16. Leahy DE, Lynch J, Taylor DC. 1989. Mechanisms of absorption of small molecules. In Novel drug delivery and its therapeutic application; Prescott FF, Nimmo WS, Eds. New York: John Wiley and Sons, pp 33-44.
17. Bayer Technology Services GmbH. 2009. User Manual PK-Sim. 4:2.
18. Willmann S, Lippert J, Schmitt W. 2005. From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 1:159-168.
19. Willmann S, Höhn K, Edginton AN, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. 2007. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34:401-431.
20. Snyder WS, Cook MJ, Nasset ES, Karhausen LR, Howells GP, Tipton IH. 1975. Digestive system. In International Commission on Radiological Protection. Report of the task group on reference man. Oxford, UK: Pergamon: pp 122-151.
21. Valentin J. 2002. Annals of the ICRP-Basic anatomical and physiological data for use in radiological protection: Reference values. Oxford, UK: Pergamon.
22. Ashford M, Fell JT. 1994. Targeting drugs to the colon: Delivery systems for oral administration. J Drug Target 2:241-257.
23. Cummings JH. 1975. Absorption and secretion by the colon. Gut 16:323-329.
24. Rubinstein A. 1995. Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Drug Carrier Syst. 12:101-149.
25. Ahrens EH Jr, Blankenhorn DH, Hirsch J. 1956. Measurement of the human intestinal length in vivo and some causes of variation. Gastroenterology 31:274-284.
26. Saunders BP, Phillips RK, Williams CB. 1995. Intraoperative measurement of colonic anatomy and attachments with relevance to colonoscopy. Br J Surg 82:1491-1493.
27. Bhatnagar BN, Sharma CL, Gupta SN, Mathur MM, Reddy DC. 2004. Study on the anatomical dimensions of the human sigmoid colon. Clin Anat 17:236-243.
28. Coskun I, Yildiz H, Arslan K, Yildiz B. 2007. A geometric description of human intestine. Ital J Anat Embryol 112:27-36.
29. Thews G, Mutschler E, Vaupel P, Eds. 1999. Anatomie, Physiologie, Pathophysiologie des Menschen. 5th ed. Stuttgart: Wiss. Verl. Ges.
30. Moll K, Moll M, Eds. 2006. Anatomie-Kurzlehrbuch zum Gegenstandskatalog. München: Elsevier, Urban & Fischer.
31. Bond JH, Prentiss RA, Levitt MD. 1979. The effects of feeding on blood flow to the stomach, small bowel, and colon of the conscious dog. J Lab Clin Med 93:594-599.
32. Dinda PK, Beck IT. 1986. Arteriolar, capillary, and shunt flow gradients along the intestine in relation to the weight distribution of the mucosa, submucosa, and muscularis-A microsphere study. Can J Physiol Pharmacol 64:1127-1136.
33. Hultén L, Lindhagen J, Lundgren O. 1977. Sympathetic nervous control of intramural blood flow in the feline and human intestines. Gastroenterology 72:41-48.
34. Matheson PJ, Wilson MA, Garrison RN. 2000. Regulation of intestinal blood flow. J Surg Res 93:182-196.
35. Tortora GJ, Grabowski SR. 2003. The digestive system. In Principles of anatomy and physiology; Tortora GJ, Grabowski SR, Ed. 10th ed. New York: Wiley, pp 851-905.
36. Yamano M, Ono K. 1990. Ultrastructure of surface epithelial cells of the normal human rectum. Z Mikrosk Anat Forsch 104:673-686.
37. Shamsuddin AM, Phelps PC, Trump BF. 1982. Human large intestinal epithelium: Light microscopy, histochemistry, and ultrastructure. Hum Pathol 13:790-803.
38. Bauer KH, Frömming K, Führer C. 2002. Lehrbuch der pharmazeutischen technologie. 7th ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH.
39. Snipes RL. 1997. Intestinal absorptive surface in mammals of different sizes. Adv Anat Embryol Cell Biol 138:1-90.
40. Porter CJ, Charman WN. 2001. Intestinal lymphatic drug transport: An update. Adv Drug Deliv Rev 50:61-80.
41. Charman WN, Porter CJ, Mithani S, Dressman JB. 1997. Physiochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharm Sci 86:269-282.
42. Yang J, Tucker GT, Rostami-Hodjegan A. 2004. Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther 76:391.
43. Corazza GR, Frazzoni M, Gatto MR, Gasbarrini G. 1986. Ageing and small-bowel mucosa: A morphometric study. Gerontology 32:60-65.
44. Crowe PT, Marsh MN. 1993. Morphometric analysis of small intestinal mucosa. IV. Determining cell volumes. Virchows Arch A Pathol Anat Histopathol 422:459-466.
45. Howdle PD, Corazza GR, Bullen AW, Losowsky MS. 1981. Gluten sensitivity of small intestinal mucosa in vitro: Quantitative assessment of histologic change. Gastroenterology 80:442-450.
46. Lipski PS, Bennett MK, Kelly PJ, James OF. 1992. Ageing and duodenal morphometry. J Clin Pathol 45:450-452.
47. Persson E. 2006. Drug dissolution under physiologically relevant conditions in vitro and in vivo. Ph.D. Thesis. Sweden: Uppsala University.
48. Stenling R, Fredrikzon B, Nyhlin H, Helander HF, Falkmer S. 1984. Surface ultrastructure of the small intestine mucosa in healthy children and adults: A scanning electron microscopic study with some methodological aspects. Ultrastruct Pathol 6:131-140.
49. Niazi NM, Leigh R, Crowe P, Marsh MN. 1984. Morphometric analysis of small intestinal mucosa. I. Methodology, epithelial volume compartments and enumeration of inter-epithelial space lymphocytes. Virchows Arch A Pathol Anat Histopathol 404:49-60.
50. Slavin G, Sowter C, Robertson K, McDermott S, Paton K. 1980. Measurement in jejunal biopsies by computer-aided microscopy. J Clin Pathol 33:254-261.
51. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. 1997. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
52. Eide TJ. 1986. A morphometrical analysis of dysplasia in small adenomas of the large intestine. Virchows Arch A Pathol Anat Histopathol 410:119-124.
53. Ensari A, Marsh MN, Loft DE, Morgan S, Moriarty K. 1993. Morphometric analysis of intestinal mucosa. V. Quantitative histological and immunocytochemical studies of rectal mucosae in gluten sensitivity. Gut 34:1225-1229.
54. Berezhkovskiy LM. 2004. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 93:1628-1640.
55. Poulin P, Schoenlein K, Theil FP. 2001. Prediction of adipose tissue: Plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 90:436-447.
56. Poulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91:1358-1370.
57. Poulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129-156.
58. Poulin P, Theil FP. 2000. A priori prediction of tissue: Plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89:16-35.
59. Schmitt W. 2008. General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro 22:457-467.
60. Rodgers T, Leahy D, Rowland M. 2005. Tissue distribution of basic drugs: Accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. J Pharm Sci 94:1237-1248.
61. Rodgers T, Rowland M. 2007. Mechanistic approaches to volume of distribution predictions: Understanding the processes. Pharm Res 24:918-933.
62. Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals, and zwitterions. J Pharm Sci 95:1238-1257.
63. Rodgers T, Leahy D, Rowland M. 2005. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1276.
64. Rabinowitz JL, Cerda JJ, Tavares CJ. 1975. Lipids and other components of human jejunal and ileal mucosa. Res Commun Chem Pathol Pharmacol 10:511-523.
65. Robinson JW, Menge H, Sepulveda FV, Mirkovitch V. 1977. Functional and structural characteristics of the jejunum and ileum in the dog and the rat. Digestion 15:188-199.
66. Schmidt RF, Thews G. 1995. Physiologie des Menschen. 26th ed. Berlin/Heidelberg/ New York: Springer Verlag.
67. US Department of Health and Human Services. 2002. Food-effect bioavailability and fed bioequivalence studies (Guidance for industry).
68. Diem K, Lentner C. 1970. Documenta geigy: Scientific tables. 7th ed. New York: Geigy Pharmaceuticals.
69. Dressman JB, Amidon GL, Reppas C, Shah VP. 1998. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res 15:11-22.
70. Lydon A, Murray C, McGinley J, Plant R, Duggan F, Shorten G. 1999. Cisapride does not alter gastric volume or pH in patients undergoing ambulatory surgery. Can J Anaesth 46:1181-1184.
71. Maltby JR, Sutherland AD, Sale JP, Shaffer EA. 1986. Preoperative oral fluids: Is a five-hour fast justified prior to elective surgery? Anesth Analg 65:1112-1116.
72. Schiller C, Fröhlich CP, Giessmann T, Siegmund W, Mönnikes H, Hosten N, Weitschies W. 2005. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther 22:971-979.
73. Kalantzi L, Persson E, Polentarutti B, Abrahamsson B, Goumas K, Dressman JB, Reppas C. 2006. Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm Res 23:1373-1381.
74. Lindahl A, Ungell AL, Knutson L, Lennernäs H. 1997. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm Res 14:497-502.
75. Tortora GJ, Derrickson BH, Eds. 2006. Anatomie und Physiologie. Weinheim: Wiley-VCH.
76. Krause WJ. 2000. Brunner's glands: A structural, histochemical and pathological profile. Prog Histochem Cytochem 35:259-367.
77. DeSesso JM, Jacobson CF. 2001. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol 39:209-228.
78. Schiller C. 2005. Untersuchungen zur Nutzung physiologischer Prinzipien bei der Entwicklung von festen oralen Arzneiformen. Ph.D. Thesis. Germany: Universität Greifswald
79. Kalantzi L, Goumas K, Kalioras V, Abrahamsson B, Dressman JB, Reppas C. 2006. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res 23:165-176.
80. Persson E, Gustafsson AS, Carlsson AS, Nilsson RG, Knutson L, Forsell P, Hanisch G, Lennernäs H, Abrahamsson B. 2005. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res 22:2141-2151.
81. Cummings JH. 2001. The effect of dietary fiber on fecal weight and composition. In CRC handbook of dietary fiber in human nutrition; Spiller GA, Ed. 3rd ed., pp 183-252.
82. Diakidou A, Vertzoni M, Goumas K, Soderlind E, Abrahamsson B, Dressman J, Reppas C. 2009. Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults. Pharm Res 26:2141-2151.
83. Scolapio JS, Camilleri M, von der Ohe MR, Hanson RB. 1995. Ascending colon response to feeding: Evidence for a 5-hydroxytryptamine-3 mechanism. Scand J Gastroenterol 30:562-567.
84. McConnell EL, Fadda HM, Basit AW. 2008. Gut instincts: Explorations in intestinal physiology and drug delivery. Int J Pharm 364:213-226.
85. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, Jarvenpaa KM. 1990. Upper gastrointestinal (GI) pH in young, healthy men, and women. Pharm Res 7:756-761.
86. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. 1989. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther 3:605-613.
87. Fallingborg J. 1999. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 46:183-196.
88. Kararli TT. 1995. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351-380.
89. Press AG, Hauptmann IA, Hauptmann L, Fuchs B, Fuchs M, Ewe K, Ramadori G. 1998. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther 12:673-678.
90. Ovesen L, Bendtsen F, Tage-Jensen U, Pedersen NT, Gram BR, Rune SJ. 1986. Intraluminal pH in the stomach, duodenum, and proximal jejunum in normal subjects and patients with exocrine pancreatic insufficiency. Gastroenterology 90:958-962.
91. Pye G, Evans DF, Ledingham S, Hardcastle JD. 1990. Gastrointestinal intraluminal pH in normal subjects and those with colorectal adenoma or carcinoma. Gut 31:1355-1357.
92. Picarelli A, diGiovambattista F, Cedrone C, diTola M, Sabbatelle L, diCello T, Sera F, Vernia P. 1998. Quantitative analysis of stool losses in adult celiac disease: Use of near-infrared analysis reconsidered. Scand J Gastroenterol 33:1052-1056.
93. Davis SS, Hardy JG, Fara JW. 1986. Transit of pharmaceutical dosage forms through the small intestine. Gut 27:886-892.
94. Meyer JH, Thomson JB, Cohen MB, Shadchehr A, Mandiola SA. 1979. Sieving of solid food by the canine stomach and sieving after gastric surgery. Gastroenterology 76:804-813.
95. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. 1999. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 36:233-254.
96. Chvasta TE, Cooke AR. 1971. Emptying and absorption of caffeine from the human stomach. Gastroenterology 61:838-843.
97. Hunt JN, Macdonald I. 1954. The influence of volume on gastric emptying. J Physiol 126:459-474.
98. Hunt JN, Stubbs DF. 1975. The volume and energy content of meals as determinants of gastric emptying. J Physiol 245:209-225.
99. Mundy MJ, Wilson CG, Hardy JG. 1989. The effect of eating on transit through the small intestine. Nucl Med Commun 10:45-50.
100. Prokop EK, Caride VJ, Marano AR, McCallum R. 1984. Scintigraphic determination of small intestinal transit time of water in man. J Nucl Med 25:97.
101. Yu LX, Crison JR, Amidon GL. 1996. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 140:111-118.
102. Dilger U. 1996. Gastrointestinaler Transit einer definierten Testmahlzeit durch Magen, Dünndarm und Dickdarm bei chronischem Alkoholabusus. Ph.D. Thesis. Germany: Universitätsklinik der Ruhr-Universität Bochum.
103. Kim SK. 1968. Small intestine transit time in the normal small bowel study. Am J Roentgenol Radium Ther Nucl Med 104:522-524.
104. Cummings JH, Bingham SA, Heaton KW, Eastwood MA. 1992. Fecal weight, colon cancer risk, and dietary intake of nonstarch polysaccharides (dietary fiber). Gastroenterology 103:1783-1789.
105. Cummings JH. 1997. The large intestine in nutrition and disease. Institut Danone. Available from.
106. Gonenne J, Camilleri M, Ferber I, Burton D, Baxter K, Keyashian K, Foss J, Wallin B, Du W, Zinsmeister AR. 2005. Effect of alvimopan and codeine on gastrointestinal transit: A randomized controlled study. Clin Gastroenterol Hepatol 3:784-791.
107. Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. 1987. Simplified assessment of segmental colonic transit. Gastroenterology 92:40-47.
108. Dressman JB, Thelen K, Jantratid E. 2008. Towards quantitative prediction of oral drug absorption. Clin Pharmacokinet 47:655-667.
109. Lin JH, Chiba M, Baillie TA. 1999. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-157.
110. Lee E, Schiller LR, Fordtran JS. 1988. Quantification of colonic lamina propria cells by means of a morphometric point-counting method. Gastroenterology 94:409-418.
111. Mahida YR, Galvin AM, Gray T, Makh S, McAlindon ME, Sewell HF, Podolsky DK. 1997. Migration of human intestinal lamina propria lymphocytes, macrophages and eosinophils following the loss of surface epithelial cells. Clin Exp Immunol 109:377-386.
112. Skinner SA, O'Brien PE. 1996. The microvascular structure of the normal colon in rats and humans. J Surg Res 61:482-490.
113. Loidl-Stahlhofen A, Hartmann T, Schottner M, Rohring C, Brodowsky H, Schmitt J, Keldenich J. 2001. Multilamellar liposomes and solid-supported lipid membranes (TRANSIL): Screening of lipid-water partitioning toward a high-throughput scale. Pharm Res 18:1782-1788.
114. Loidl-Stahlhofen A, Eckert A, Hartmann T, Schottner M. 2001. Solid-supported lipid membranes as a tool for determination of membrane affinity: High-throughput screening of a physicochemical parameter. J Pharm Sci 90:599-606.
115. Xiang TX, Anderson BD. 1994. The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol 140:111-122.
116. Walter A, Gutknecht J. 1986. Permeability of small nonelectrolytes through lipid bilayer membranes. J Membr Biol 90:207-217.
117. Cohen BE, Bangham AD. 1972. Diffusion of small non-electrolytes across liposome membranes. Nature 236:173-174.
118. Lieb WR, Stein WD. 1969. Biological membranes behave as non-porous polymeric sheets with respect to the diffusion of non-electrolytes. Nature 224:240-243.
119. Lennernas H. 1998. Human intestinal permeability. J Pharm Sci 87:403-410.
120. Lennernas H. 2007. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 37:1015-1051.
121. Bircher J, Sommer W, Eds. 1999. Klinisch-pharmakologische Datensammlung. Stuttgart: Wiss. Verl.-Ges.
122. Wessel MD, Jurs PC, Tolan JW, Muskal SM. 1998. Prediction of human intestinal absorption of drug compounds from molecular structure. J Chem Inf Comput Sci 38:726-735.
123. Balon K, Riebesehl BU, Muller BW. 1999. Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption. Pharm Res 16:882-888.
124. Kansy M, Senner F, Gubernator K. 1998. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 41:1007-1010.
125. Palm K, Stenberg P, Luthman K, Artursson P. 1997. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 14:568-571.
126. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. 2006. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34:D668-D672.
127. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. 2008. DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36:D901-D906.
128. Bourdet DL, Pollack GM, Thakker D. 2006. Intestinal absorptive transport of the hydrophilic cation ranitidine: A kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in caco-2 cells. Pharm Res 23:1178-1187.
129. Gan LS, Hsyu PH, Pritchard JF, Thakker D. 1993. Mechanism of intestinal absorption of ranitidine and ondansetron: Transport across Caco-2 cell monolayers. Pharm Res 10:1722-1725.
130. Pade V, Stachansky S. 1997. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm Res 14:1210-1215.
131. Shojaei AH, Berner B, Xiaoling L. 1998. Transbuccal delivery of acyclovir: I. In vitro determination of routes of buccal transport. Pharm Res 15:1182-1188.
132. Alsenz J, Meister E, Haenel E. 2007. Development of a partially automated solubility screening (PASS) assay for early drug development. J Pharm Sci 96:1748-1762.
133. Arnal J, Gonzalez-Alvarez I, Bermejo M, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir. J Pharm Sci 97:5061-5073.
134. Chuasuwan B, Binjesoh V, Polli JE, Zhang H, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Diclofenac sodium and diclofenac potassium. J Pharm Sci 98:1206-1219.
135. Devarakonda B, Otto DP, Judefeind A, Hill RA, de Villiers MM. 2007. Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. Int J Pharm 345:142-153.
136. Hardman JG, Goodman LS. 2001. Goodman and Gilman's The pharmacological basis of therapeutics; Hardman JG, Limbird LE, Goodman Gilman A, Eds. 10th ed. New York: McGraw-Hill.
137. Jantratid E, Prakongpan S, Dressman JB, Amidon GL, Junginger HE, Midha KK, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine. J Pharm Sci 95:974-984.
138. Obata K, Sugano K, Machida M, Aso Y. 2004. Biopharmaceutics classification by high throughput solubility assay and PAMPA. Drug Dev Ind Pharm 30:181-185.
139. Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB. 2009. Predicting pharmacokinetics of drugs using physiologically based modeling-Application to food effects. AAPS J 11:45-53.
140. Roy D, Ducher F, Laumain A, Legendre JY. 2001. Determination of the aqueous solubility of drugs using a convenient 96-well plate-based assay. Drug Dev Ind Pharm 27:107-109.
141. Shalaeva M, Kenseth J, Lombardo F, Bastin A. 2008. Measurement of dissociation constants (pKa values) of organic compounds by multiplexed capillary electrophoresis using aqueous and cosolvent buffers. J Pharm Sci 97:2581-2606.
142. Somogyi A, Gugler R. 1983. Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet 8:463-495.
143. Sweetman SC. Martindale: The Complete Drug Reference. Accessed January 25, 2010, at.
144. Wiedmann TS, Kamel L. 2002. Examination of the solubilization of drugs by bile salt micelles. J Pharm Sci 91:1743-1764.
145. GlaxoSmithKline GmbH & Co.KG. 2002. Fachinformation Zovirax Suspension. www.fachinfo.de, Rote Liste Service GmbH.
146. Laskin OL, Longstreth JA, Saral R, de MP, Keeney R, Lietman PS. 1982. Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. Antimicrob Agents Chemother 21:393-398.
147. O'Brien JJ, Campoli-Richards DM. 1989. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 37:233-309.
148. Vergin H, Kikuta C, Mascher H, Metz R. 1995. Pharmacokinetics and bioavailability of different formulations of aciclovir. Arzneimittelforschung 45:508-515.
149. de Miranda P, Blum MR. 1983. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 12(Suppl B):29-37.
150. Palma-Aguirre JA, Absalon-Reyes JA, Novoa-Heckel G, de Oliva I, Rodriguez Z, Gonzalez-de la PM, Burke-Fraga V, Namur S. 2007. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400mg: Two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. Clin Ther 29:1146-1152.
151. Wu C, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
152. Blanchard J. 1982. Protein binding of caffeine in young and elderly males. J Pharm Sci 71:1415-1418.
153. Newton R, Broughton LJ, Lind MJ, Morrison PJ, Rogers HJ, Bradbrook ID. 1981. Plasma and salivary pharmacokinetics of caffeine in man. Eur J Clin Pharmacol 21:45-52.
154. Blanchard J, Sawers SJ. 1983. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol 24:93-98.
155. Walkenstein SS, Dubb JW, Randolph WC, Westlake WJ, Stote RM, Intoccia AP. 1978. Bioavailability of cimetidine in man. Gastroenterology 74:360-365.
156. CT Arzneimittel GmbH. 2007. Fachinformation Cimetidin-CT 400mg Filmtabletten. www.fachinfo.de, Rote Liste Service GmbH.
157. Lotsch J, Kettenmann B, Renner B, Drover D, Brune K, Geisslinger G, Kobal G. 2000. Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: Relation to pharmacodynamics in an experimental pain model. Pharm Res 17:77-84.
158. Davies NM, Anderson KE. 1997. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet 33:184-213.
159. John VA. 1979. The pharmacokinetics and metabolism of diclofenac sodium (Voltarol) in animals and man. Rheumatol Rehabil Suppl 2:22-37.
160. Novartis Pharma GmbH. 2008. Fachinformation Voltaren Dispers. www.fachinfo.de, Rote Liste Service GmbH.
161. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG. 1979. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 16:405-410.
162. Degen PH, Dieterle W, Schneider W, Theobald W, Sinterhauf U. 1988. Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. Xenobiotica 18:1449-1455.
163. Granero GE, Longhi MR, Mora MJ, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Furosemide. J Pharm Sci 99:2544-2556.
164. Beermann B, Dalen E, Lindstrom B, Rosen A. 1975. On the fate of furosemide in man. Eur J Clin Pharmacol 9:51-61.
165. Sanofi-Aventis Deutschland GmbH. 2009. Fachinformation Lasix liquidum. www.fachinfo.de, Rote Liste Service GmbH.
166. Waller ES, Hamilton SF, Massarella JW, Sharanevych MA, Smith RV, Yakatan GJ, Doluisio JT. 1982. Disposition and absolute bioavailability of furosemide in healthy males. J Pharm Sci 71:1105-1108.
167. Kalantzi L, Reppas C, Dressman JB, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky SA, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (paracetamol). J Pharm Sci 95:4-14.
168. Morris ME, Levy G. 1984. Renal clearance and serum protein binding of acetaminophen and its major conjugates in humans. J Pharm Sci 73:1038-1041.
169. Clements JA, Heading RC, Nimmo WS, Prescott LF. 1978. Kinetics of acetaminophen absorption and gastric emptying in man. Clin Pharmacol Ther 24:420-431.
170. Rawlins MD, Henderson DB, Hijab AR. 1977. Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharmacol 11:283-286.
171. Farre M, Roset PN, Abanades S, Menoyo E, Alvarez Y, Rovira M, Baena A. 2008. Study of paracetamol 1-g oral solution bioavailability. Methods Find Exp Clin Pharmacol 30:37-41.
172. DESITIN Arzneimittel GmbH. 2010. Fachinformation Luminal/Luminaletten. www.fachinfo.de, Rote Liste Service GmbH.
173. Wilensky AJ, Friel PN, Levy RH, Comfort CP, Kaluzny SP. 1982. Kinetics of phenobarbital in normal subjects and epileptic patients. Eur J Clin Pharmacol 23:87-92.
174. Nelson E, Powell JR, Conrad K, Likes K, Byers J, Baker S, Perrier D. 1982. Phenobarbital pharmacokinetics and bioavailability in adults. J Clin Pharmacol 22:141-148.
175. Meyer MC, Straughn AB, Raghow G, Schary WL, Rotenberg KS. 1984. Absorption of phenobarbital from tablets and elixir. J Pharm Sci 73:485-488.
176. Ogilvie RI. 1978. Clinical pharmacokinetics of theophylline. Clin Pharmacokinet 3:267-293.
177. Hendeles L, Weinberger M, Bighley L. 1977. Absolute bioavailability of oral theophylline. Am J Hosp Pharm 34:525-527.
178. Kaumeier HS, Kehrhahn OH, Neugebauer G, Schuppan D, Schwarz JA, Staib AH. 1984. A cross-over study of oral and intravenous administration of theophylline in male volunteers. Absolute bioavailability of theophylline tablets. Arzneimittelforschung 34:92-95.
179. Axelrod J, Reichenthal J. 1953. The fate of caffeine in man and a method for its estimation in biological material. J Pharmacol Exp Ther 107:519-523.
180. Forrest JA, Clements JA, Prescott LF. 1982. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet 7:93-107.
181. Heading RC, Nimmo J, Prescott LF, Tothill P. 1973. The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmacol 47:415-421.
182. Staib AH, Loew D, Harder S, Graul EH, Pfab R. 1986. Measurement of theophylline absorption from different regions of the gastro-intestinal tract using a remote controlled drug delivery device. Eur J Clin Pharmacol 30:691-697.
183. Yee S. 1997. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-Fact or myth. Pharm Res 14:763-766.
184. Zhou SY, Piyapolrungroj N, Pao L, Li C, Liu G, Zimmermann E, Fleisher D. 1999. Regulation of paracellular absorption of cimetidine and 5-aminosalicylate in rat intestine. Pharm Res 16:1781-1785.
185. Wilson CG, Washington N, Hardy JG, Bond SW. 1987. The influence of food on the absorption of acyclovir: A pharmacokinetic and scintigraphic assessment. Int J Pharm 38:221-225.
186. Kaneniwa N, Funaki T, Furuta S, Watari N. 1986. Study of the absorption site of cimetidine. J Pharmacobiodyn 9:321-326.
187. Collett A, Higgs NB, Sims E, Rowland M, Warhurst G. 1999. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp Ther 288:171-178.
188. Dahan A, Amidon GL. 2009. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm 6:19-28.
189. Wienkers LC, Heath TG. 2005. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833.
190. Wilkinson GR. 2005. Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211-2221.